Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost-Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden.

Johan Jendle¹, Colin Hopley², Anuj Narang³, Raffaele Scarica², Helena Hellerstedt⁴, Melanie Littlewood²

¹Institute of Medical Sciences, Örebro University, Örebro, Sweden.

²Insulet, London, UK.

³IQVIA, Gurgaon, India.

⁴Nordic Infucare AB, Bromma, Sweden.

PubMed DOI

Abstract

AIM: Analyse the cost-effectiveness of the Omnipod 5 automated insulin delivery system versus multiple daily injections (MDI) with continuous glucose monitoring for type 1 diabetes among adults in Sweden. METHODS: Cost-effectiveness was analysed with the IQVIA Core Diabetes Model (version 10.0) taking the perspective of the payer in Sweden including healthcare system and combined healthcare syste…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.